All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

Double-blind, randomised, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patients with corticobasal syndrome (CBS)

This clinical trial is testing a liquid medicine called glycerol phenylbutyrate (also known as Ravicti) in people with corticobasal syndrome (CBS). CBS is a rare brain condition that causes problems with movement, balance, and thinking. Researchers want to find out if this medicine can protect nerve cells from damage. To measure this, they will test participants' blood for a protein called NfL. High levels of this protein usually mean nerve cells are under stress or breaking down. Participants will be placed into one of two groups: one receives the actual medicine and the other receives a dummy liquid (placebo). Neither the patients nor the doctors will know who gets which treatment. Researchers will monitor safety, side effects, and changes in daily movement and memory throughout the study to see if the medicine helps.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
Enrolment target
32
Start
26 Sep 2024

What is this study about?

Corticobasal syndrome (CBS) is a rare neurological condition that affects movement, speech, balance, and memory. Over time, nerve cells in the brain become damaged and stop working properly. Currently, there is no cure for CBS, and existing treatments only help manage symptoms rather than stopping the illness itself. Finding treatments that can protect brain cells is an urgent goal for doctors and researchers.

This study is testing an oral liquid medicine called glycerol phenylbutyrate. Researchers believe this medicine may help brain cells clear out waste products and stay healthy for longer. To test if it works, the study looks at a specific protein in the blood called neurofilament light chain (NfL). When brain cells are injured, NfL leaks into the bloodstream. If the medicine lowers or stabilises these protein levels, it could mean it is successfully protecting brain cells.

Because this is a Phase II study, the main goals are to check whether the medicine is safe, easy to tolerate, and whether it shows early signs of working. The findings from this trial will help scientists decide if the treatment should be tested in larger, longer clinical trials in the future.

Key takeaways

  • Tests whether a liquid medicine can protect nerve cells in people with corticobasal syndrome (CBS).
  • Uses a blood test to measure a protein (NfL) linked to brain cell health.
  • Compares the active drug against an inactive dummy liquid (placebo).
  • Monitors your safety closely with physical exams, vital signs, and blood tests.
  • Participation is voluntary, and you can leave the study at any time.

Who may be eligible?

This trial is open to adults aged 18 and older who have received a diagnosis of corticobasal syndrome (CBS). Both men and women can take part.

Because the study involves regular clinic visits, blood tests, and physical checks, participants must be well enough to attend appointments and complete simple memory and movement tasks.

Doctors will review each person's general health, medical history, and current medicines before they can join. People with certain other severe medical conditions or those unable to swallow liquid medicine may not be able to participate.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I have been diagnosed with corticobasal syndrome (CBS).
  3. I am able and willing to swallow a daily liquid medicine.
  4. I can attend regular hospital visits for health tests and blood samples.
  5. I am willing to complete simple movement and memory assessments.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves taking a liquid medicine by mouth every day. Half of the participants will receive the real medicine, and the other half will receive an inactive dummy medicine (placebo). A computer decides who gets which liquid at random, and neither you nor your study doctor will know which one you are taking.

You will need to attend hospital visits for regular health checks. During these appointments, the study team will take blood samples, measure your blood pressure and heart rate, and perform gentle neurological and physical examinations.

You will also complete simple questionnaires and movement tests to track your walking, balance, memory, and everyday quality of life. The study team will closely monitor your wellbeing throughout, and you will have regular contact with the doctors to check for any unwanted side effects.

Potential risks and benefits

Taking part in this trial may not directly improve your symptoms, but it could help doctors discover new ways to treat corticobasal syndrome in the future. As with any medicine, there is a risk of side effects, such as stomach upset or mild reactions to the liquid. You will have regular health checks so any problems can be spotted early. Joining is entirely your choice, and you can withdraw from the study at any time without giving a reason and without your normal medical care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What is corticobasal syndrome (CBS)?

CBS is a rare condition where nerve cells in parts of the brain gradually stop working, causing stiffness, poor balance, muscle jerks, and difficulties with thinking.

What is a placebo?

A placebo is a dummy treatment that looks and tastes like the real medicine but contains no active ingredients. It helps researchers see if the real drug truly works.

How is the study medicine taken?

The medicine is an oral liquid that you swallow, taken by mouth according to instructions given by the study team.

Why are blood tests needed?

Blood tests measure a protein called NfL, which shows how healthy your brain cells are, and ensure your liver and kidneys stay safe.

Do I have to pay to take part?

No, clinical trial medicines and study tests are provided free of charge, and travel expenses are often covered.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Double-blind, randomised, prospective, placebo controlled pa…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.